Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Summary of the study.

New drug is first to help patients with recurrent low-grade ovarian cancer

Donating to research gives women access to life prolonging drugs through clinical trials. Drugs like Selumetinib. Selumetinib belongs to a drug class called MEK inhibitors. This class of drugs is more commonly used in melanoma. The phase 2 study published in the Lancet found 50% of women had a progression free survival (non-growth of their cancer) of 11 months.

But a few women did much better. Women like Dotsy Elliot whose tumours shrunk on the treatment. For over five years Selumetinib has kept her healthy enough to work full-time.

Researchers are now searching for ways to reduce resistance to MEK inhibitors. So that more women can benefit from medications like Selumetinib.

Your donation through Cure Our Ovarian Cancer supports research to make a real difference to women’s lives.

Share this: